Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

C-myc Biomarker Study for Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04591691
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : March 25, 2022
Sponsor:
Collaborators:
Indiana University
Stanford University
University of Miami
University of Pittsburgh
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Cathie Spino, ScD, University of Michigan

Brief Summary:
This is a multi-center observational cohort study of patients with diabetic foot ulcers (DFU) to develop and validate potential tissue-based biomarkers that predict complete wound healing. Eligible and consented participants will begin standard of care treatment after collection of tissue specimens from the wound's edge. An additional tissue specimen is collected at 4 weeks if clinically indicated. Tissues will be tested for c-myc and phosphorylated glucocorticoid receptor (p-GR) levels using validated protocols at a central laboratory. Participants will be followed weekly for up to 12 weeks or until complete wound healing (whichever occurs first). One final assessment 2 weeks after complete wound healing will occur to confirm healing.

Condition or disease
Diabetes Diabetic Foot Diabetic Foot Ulcer Diabetic Wound

Layout table for study information
Study Type : Observational
Estimated Enrollment : 213 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predictive and Diagnostic Biomarkers for Diabetic Foot Ulcers - C-myc and Phosphorylated Glucocorticoid Receptor
Actual Study Start Date : October 14, 2020
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements [ Time Frame: Up to 12 weeks ]

Biospecimen Retention:   Samples Without DNA
Wound edge issue specimens are collected from the wound edge at Week 0 and, if clinically indicated, at Week 4 of the study. Investigators sample full thickness skin of a wound edge that includes epidermis and dermis.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult Type 1 or Type 2 Diabetic patients with a diabetic foot ulcer
Criteria

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18 years or older.
  4. Clinically diagnosed with diabetes or meeting the American Diabetes Association (ADA) criteria.
  5. Foot ulcer of diabetic etiology, with all of the following characteristics:

    1. Ulcer size > 0.5 cm2 and < 12 cm2 at least 2 cm from any other ulcer, and
    2. Ulcer with Wagner grade 1 or 2 In case of multiple ulcers, select the largest ulcer that meets inclusion criteria.
  6. Patients with neuropathic or neuro-ischemic ulcers with adequate circulation to allow healing to the affected extremity as demonstrated by at least 2 of the following within 6 months of Visit 1:

    1. Ankle brachial index (ABI) ≥ 0.6 with Doppler Waveforms, or
    2. Absolute ankle pressure ≥ 70 mm Hg, or
    3. Toe pressure ≥ 40 mmHg, or
    4. TcPO2 ≥ 40 mmHg
  7. Willingness to comply with standard of care which includes an initial surgical debridement of the wound.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Patient participating in an interventional clinical trial within 1 month of Visit 1
  2. Currently receiving radiation to target area or chemotherapy
  3. Participants with Charcot's foot or other foot deformities that prevents adequate targeted ulcer offloading
  4. Participant with active severe infection or osteomyelitis at the time of screening
  5. History of cancer within last 3 years, other than non-melanoma skin cancer
  6. Known or suspected malignancy of current study ulcer
  7. Use of adjunctive therapy within previous 30 days
  8. Currently receiving medication considered to be systemic glucocorticoids
  9. Plan to perform a vascular intervention, such as surgical bypass, angioplasty or stenting, or < 1 month from a prior ipsilateral vascular intervention
  10. Any history of concomitant medical condition that, in the opinion of the investigator(s), would compromise the participant's ability to safely complete the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04591691


Contacts
Layout table for location contacts
Contact: Katy Clark 734-615-6767 DFC-DCC-PM@umich.edu
Contact: Tanvi Naik 805-391-6777 DFC-DCC-PM@umich.edu

Locations
Layout table for location information
United States, California
University of California - San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Onorio Antonucci    415-353-4379    onorio.antonucci@ucsf.edu   
Principal Investigator: Michael Conte, MD         
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Shannon Meyer       smeyer72@stanford.edu   
Principal Investigator: Geoffrey Gurtner, MD, FACS         
United States, Florida
University of Miami Active, not recruiting
Miami, Florida, United States, 33126
United States, Indiana
Indiana University Health Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Bryce Hockman    317-278-2715    bbhockma@iu.edu   
Contact: Henry Ludwig    317-504-5785    hbludwig@iu.edu   
Principal Investigator: Chandan K Sen, PhD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Aaron Burant    734-615-0552    aburant@med.umich.edu   
Principal Investigator: Rodica Pop-Busui, MD, PhD         
United States, Pennsylvania
University of Pittsburgh Active, not recruiting
Pittsburgh, Pennsylvania, United States, 25261
Sponsors and Collaborators
University of Michigan
Indiana University
Stanford University
University of Miami
University of Pittsburgh
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Marjana Tomic-Canic University of Miami
Layout table for additonal information
Responsible Party: Cathie Spino, ScD, Research Professor of Biostatistics, SABER Director, University of Michigan
ClinicalTrials.gov Identifier: NCT04591691    
Other Study ID Numbers: HUM00168547
1U24DK122927-01 ( U.S. NIH Grant/Contract )
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: March 25, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cathie Spino, ScD, University of Michigan:
biomarker
C-myc
phosphorylated glucocorticoid receptor
DFC
Diabetic Foot Consortium
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases